Daniel Crona, Pharm.D., Ph.D., CPP
1077 Genetic Medicine Building, 120 Mason Farm Road, CB# 7361, Chapel Hill, NC, 27599
Daniel J. Crona, Pharm.D., Ph.D., CPP is an assistant professor in the Division of Pharmacotherapy and Experimental Therapeutics in the UNC Eshelman School of Pharmacy. In 2006, he received his B.S. from the University of Colorado-Denver, where he majored in Biology and worked as a research associate at the University of Colorado Center for Genetic Lung Disease. In 2010, he received his Pharm.D. from the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, where his honors research was a translational project that focused quantification of hormones and cytokines related to gastric motility in critically ill patients. In 2015, he received his Ph.D. from the UNC Eshelman School of Pharmacy, and his dissertation focused on the identification and validation novel germline genetic variants that associated with survival in patients with advanced or metastatic kidney cancer treated with sorafenib. He finished his training as an NIGMS-funded post-doctoral fellow in the UNC/Duke/Hamner Institute collaborative T32 training program in clinical pharmacology.
Crona is registered pharmacist in the state of North Carolina, and is licensed as a Clinical Pharmacist Practitioner at the UNC Medical Center, where his clinical practice is focused on genitourinary malignancies. He has been trained as a pharmaceutical scientist and clinical pharmacologist, with expertise in precision medicine/pharmacogenetics, developmental therapeutics, and epigenetics. His overarching career goal is to advance public health by integrating epigenetics, developmental therapeutics, and clinical pharmacology into clinical and translational research that optimizes treatment strategies for hematology/oncology patients. His highly collaborative translational research program is focused on a functional genomics paradigm that helps reveal molecular mechanisms that underlie the interplay between patient genotype, phenotype, and epigenetics. Molecular mechanistic information is then integrated with clinical pharmacology (e.g., pharmacokinetics and pharmacodynamics) to optimize drug selection and dosing. He has received funding from the UNC Eshelman Institute for Innovation, the NC TraCS Institute, the American College of Clinical Pharmacy, the Hematology Oncology Pharmacy Association, IBM, and Merck.
Since the beginning of his faculty appointment at the UNC Eshelman School of Pharmacy in 2015, Crona has been active in teaching and mentoring post-doctoral residents and fellows, graduate students, professional students, and undergraduates. He has mentored 4 post-doctoral researchers, 6 PGY-2 hematology/oncology residency research projects, 5 PharmD honors students, several UNC undergraduates, and he is currently the major research advisor for 3 graduate students. He is also currently the Director for Graduate Studies in the Division of Pharmacotherapy and Experimental Therapeutics.
Aside from his faculty appointment in the Division of Pharmacotherapy and Experimental Therapeutics, he is also faculty in the Pharmacogenomics and Individualized Therapy Program, faculty in the Molecular Therapeutics program at the UNC Lineberger Comprehensive Cancer Center, and faculty in the UNC Chromatin and Epigenetics Program.
Precision Dosing of TKIs for Real World Patients with Chronic Myelogenous Leukemia through Advanced PKPD Modeling
- Post-Doctoral Fellowship, UNC/Duke T32/Hamner Institute Clinical Pharmacology Program
- Ph.D., University of North Carolina Eshelman School of Pharmacy
- Pharm.D., University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
- B.S., University of Colorado- Denver
- B.A., Monmouth College
Daniel Crona News